Current Insights and Progress in the Clinical Management of Head and Neck Cancer

Amaral, Mariana; Faísca, Pedro; Ferreira, Hugo Alexandre; Gaspar, Maria Manuela; Reis, Catarina Pinto

doi:10.3390/cancers14246079

Cited by 19 publications

(17 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite signi cant advancements in the treatment of HNSCC, including surgery, radiotherapy, and chemotherapy, the disease remains challenging due to its propensity for metastasis and recurrence. Even though immunotherapy and targeted therapy have emerged as promising treatments for HNSCC in recent years, drug resistance remains a major issue 19 . The IGF2BPs gene family is an RNA-binding protein containing IGF2BP1, IGF2BP2, and IGF2BP3.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Expression of the IGF2BPs gene family in Head and Neck Squamous Cell Carcinoma: Association with Prognostic Value and Tumor Immunity

Tang

Liu

Zhao

2023

Preprint

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) represents a predominant type of malignant cancer found in the head and neck region, characterized by a high incidence and unfavorable prognosis. The IGF2BPs gene family, which belongs to the RNA-binding protein class, has been critically implicated in several cancers, and its involvement in HNSCC necessitates further exploration. Objective: To explore the clinical significance and potential biological functions of the IGF2BPs gene family in HNSCC. Methods: A bioinformatic methodology was employed to examine the expression profile, diagnostic and prognostic significance, and biological mechanisms of the IGF2BPs gene family in HNSCC, with a particular emphasis on its involvement in the immune function of HNSCC. This was followed by in vitro investigations to unravel the biological roles of the IGF2BPs gene family in HNSCC. Results: This investigation has demonstrated that, in contrast with normal control tissue, HNSCC has a substantial elevation in the expression level of the IGF2BPs gene family. Patients with a high level of IGF2BPs gene family expression demonstrated higher prediction accuracy for HNSCC. Furthermore, patients with HNSCC and elevated IGF2BPs gene family expression levels exhibited poor survival outcomes. The IGF2BPs gene family displayed a significant association with a variety of immune infiltrating cells and immune genes in HNSCC. Studies conducted in vitro have confirmed that IGF2BP2 silencing suppressed the migration, proliferation, and invasion of HNSCC cells. Conclusions: It has been determined that the IGF2BPs gene family plays a crucial part in the onset and progression of HNSCC, and its association with tumor immunity has been established. The IGF2BPs gene family holds promising potential as a diagnostic and prognostic biomarker for HNSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Expression of the IGF2BPs gene family in Head and Neck Squamous Cell Carcinoma: Association with Prognostic Value and Tumor Immunity

Tang

Liu

Zhao

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The anatomic subsites of the head and neck malignant tumors include naso-, oro- and hypopharynx, larynx, nasal cavity, oral cavity, the floor of the mouth, the palate, tongue, tonsils, salivary glands, etc. [ 2 ]. Squamous cell carcinoma (SCC) accounts for approximately 90% of head and neck malignancies [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Significance of FOXD1 Expression in Head and Neck Squamous Cell Carcinoma

Jiang

et al. 2023

JPM

View full text Add to dashboard Cite

It has been reported that forkhead box D1 (FOXD1) plays an established role in human early embryonic development and is broadly involved in various malignancies. However, there is limited information regarding FOXD1 expression in head and neck squamous cell carcinoma (HNSCC). This present study aimed to explore the clinical significance of FOXD1 in patients with HNSCC. Tissue microarrays of 334 primary HNSCC patients who underwent surgery between 2008 and 2010 at Sun Yat-sen University Cancer Center were investigated by immunohistochemistry regarding FOXD1 expression. χ2 test was used to estimate the relationship of FOXD1 expression with clinicopathologic characteristics. Univariate and multivariate analyses were performed to identify FOXD1 expression as an independent prognostic indicator of overall survival (OS) and disease-free survival (DFS). FOXD1 expression is closely associated with postoperative recurrence. HNSCC patients with high FOXD1 expression have poorer prognoses than the low-expression group (p < 0.05). According to multivariate analysis, FOXD1 was an independent prognostic factor for OS and DFS. The results revealed that FOXD1 could be a prognostic factor for HNSCC and might serve as a potential target for novel therapies.

show abstract

“…Head and neck squamous cell carcinomas (HNSCCs) are epithelial malignancies that arise from mucosal surfaces of the oral cavity, pharynx, and larynx. HNSCCs are generally associated with a poor prognosis, as shown by the development of recurrences in over 50% of patients [ 1 , 2 , 3 ]. Risk factors for the development of HNSCC include behavioral risk factors, such as alcohol consumption and smoking, and human papillomavirus (HPV) infection [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC

Bernuth

Ribbat‐Idel

Klapper

et al. 2023

IJMS

View full text Add to dashboard Cite

Patients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic E3 ubiquitin ligase that was initially described as an autoantigen in autoimmune diseases and later associated with the intracellular antiviral response. Here, we investigated the role of TRIM21 as a biomarker candidate for HNSCC in predicting tumor progression and patient survival. We analyzed TRIM21 expression and its association with clinical-pathological parameters in our HNSCC cohort using immunohistochemistry. Our HNSCC cohort included samples from 419 patients consisting of primary tumors (n = 337), lymph node metastases (n = 156), recurrent tumors (n = 54) and distant metastases (n = 16). We found that cytoplasmic TRIM21 expression was associated with the infiltration of immune cells into primary tumors. In addition, TRIM21 expression was significantly higher in primary tumors than in lymph node metastases, and increased TRIM21 expression was correlated with shorter progression-free survival in HNSCC patients. These results suggest that TRIM21 could be a new biomarker for progression-free survival.

show abstract

Current Insights and Progress in the Clinical Management of Head and Neck Cancer

Cited by 19 publications

References 155 publications

Comprehensive Analysis of the Expression of the IGF2BPs gene family in Head and Neck Squamous Cell Carcinoma: Association with Prognostic Value and Tumor Immunity

Comprehensive Analysis of the Expression of the IGF2BPs gene family in Head and Neck Squamous Cell Carcinoma: Association with Prognostic Value and Tumor Immunity

The Prognostic Significance of FOXD1 Expression in Head and Neck Squamous Cell Carcinoma

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC

Contact Info

Product

Resources

About